Highly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and Urine

DOI: 10.1093/clinchem/47.4.673
Clinical Chemistry, 2001, 47, 673-680.

#	Paper	IF	Citations
530	Measurement of Free Light Chains in Urine. *Clinical Chemistry*, **2001**, 47, 2069-2070	5.5	8
529	Protein aggregation. *Clinical Chemistry and Laboratory Medicine*, **2001**, 39, 1065-75	5.9	23
528	The Pavia approach to clinical protein analysis. *Clinical Chemistry and Laboratory Medicine*, **2001**, 39, 1025-8	5.9	14
527	Immunonephelometrische Bestimmung der Leichtketten von Immunglobulinen und des Kappa/Lambda-Quotienten im Urin bei Patienten mit monoklonaler Gammopathie. Immunonephelometrical Analysis of Immunoglobulin Light Chains and Kappa/Lambda Ratio in Urine of Patients with Monoclonal Gammopathy. **2001**, 25, 541-547		
526	Autologous stem cell transplantation for primary systemic amyloidosis. **2002**, 99, 4276-82		289
525	Influence of plasma immunoglobulin level on antibody synthesis. **2002**, 100, 353-5		30
524	Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain Myeloma. *Clinical Chemistry*, **2002**, 48, 655-657	5.5	94
523	Serum Reference Intervals and Diagnostic Ranges for Free □ and Free ▯ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains. *Clinical Chemistry*, **2002**, 48, 1437-1444	5.5	498
522	Simple Method for Quantification of Bence Jones Proteins. *Clinical Chemistry*, **2002**, 48, 2202-2207	5.5	5
521	Serum free light chain immunoassays and their clinical application. **2002**, 3, 17-33		13
520	Urinary free light chain analysis by the Freelite immunoassay: a preliminary study in multiple myeloma. **2002**, 35, 565-7		18
519	Development of Quantitative Enzyme Immunoassay and Radioimmunoassay of ▯-Free Light Chains of Immunoglobulins. **2002**, 38, 493-499		
518	Diagnostik von monoklonalen Gammopathien. **2003**, 27, 8-15		
517	ELISAs for free light chains of human immunoglobulins using monoclonal antibodies: comparison of their specificity with available polyclonal antibodies. **2003**, 275, 9-17		25
516	Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. **2003**, 122, 78-84		315
515	Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. **2003**, 3, 241-6		123
514	Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions?. **2003**, 24, 181-5		76

513	Practical considerations for the measurement of free light chains in serum. *Clinical Chemistry*, **2003**, 49, 1252-7	5.5	55
512	Quantitative Analysis of Serum Free Light Chains. **2003**, 119, 274-278		148
511	Diagnostik von monoklonalen Gammopathien/Diagnostic Procedures in Monoclonal Gammopathies. **2003**, 27, 8-15		
510	Guidelines for the analysis of Bence Jones protein. *Clinical Chemistry and Laboratory Medicine*, **2003** , 41, 338-46	5.9	37
509	Measurement of Immunoglobulin Free Light Chains in Serum: Response. *Clinical Chemistry*, **2003**, 49, 1958-1958	5.5	2
508	Measurement of immunoglobulin free light chains in serum. *Clinical Chemistry*, **2003**, 49, 1957-8; author reply 1958	5.5	7
507	Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. **2003**, 119, 274-8		37
506	Ratio of urinary free immunoglobulin light chain kappa to lambda in the diagnosis of Bence Jones proteinuria. *Clinical Chemistry and Laboratory Medicine*, **2004**, 42, 429-34	5.9	9
505	Kappa free light chains in cerebrospinal fluid as markers of intrathecal immunoglobulin synthesis. *Clinical Chemistry*, **2004**, 50, 1809-13	5.5	49
504	Guidelines on the diagnosis and management of AL amyloidosis. **2004**, 125, 681-700		88
503	Serum free light chains for monitoring multiple myeloma. **2004**, 126, 348-54		128
502	ELISAs for free human immunoglobulin light chains in serum: improvement of assay specificity by using two specific antibodies in a sandwich detection method. **2004**, 293, 183-9		20
501	Functional role for Ig free light chains in immediate and delayed hypersensitivity responses. **2004**, 53 Suppl 1, S6-8		1
500	Therapy for immunoglobulin light chain amyloidosis: the new and the old. **2004**, 18, 17-37		49
499	Characterization of amyloidogenic immunoglobulin light chains directly from serum by on-line immunoaffinity isolation. **2004**, 18, 191-201		18
498	Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion. **2004**, 75, 246-8		33
497	Immune mechanisms of AL amyloidosis. **2004**, 1, 365-373		6
496	Amyloses. **2004**, 1, 46-58		2

495	Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis. **2005**, 44, 428-33		20
494	The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). **2005**, 105, 2949-51		180
493	Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. **2005**, 141, 1277-82		46
492	Role of immunoglobulin light chains in Al amyloidosis. **2005**, 44, 399-400		
491	Clinical aspects of systemic amyloid diseases. **2005**, 1753, 11-22		169
490	Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. **2005**, 36, 597-600		81
489	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. **2005**, 79, 319-28		971
488	Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. **2005**, 84, 588-93		24
487	Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry. **2005**, 25, 338-45		44
486	Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. *Clinical Chemistry*, **2005**, 51, 878-81	5.5	200
485	Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. **2005**, 11, 8706-14		71
484	Immunochemical quantification of free light chains in urine. *Clinical Chemistry*, **2005**, 51, 1033-5	5.5	3
483	Human N-terminal proBNP is a monomer. *Clinical Chemistry*, **2005**, 51, 1035-8	5.5	18
482	Correlation between serum levels of free light chain and phenotype of plasma cells in bone marrow in primary AL amyloidosis. **2005**, 12, 33-40		4
481	Evaluation of a new CA15-3 protein assay method: optical protein-chip system for clinical application. *Clinical Chemistry*, **2005**, 51, 1038-40	5.5	29
480	Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. **2005**, 12, 210-5		36
479	Serum free light chain measurements move to center stage. *Clinical Chemistry*, **2005**, 51, 805-7	5.5	57
478	Diagnosis and monitoring a case of light-chain deposition disease in the kidney using a new, sensitive immunoassay. **2005**, 20, 1251-3		11

477	Existe-t-il un intérêt à étudier par électrophorèse les protéinuries « quantitativement normales » ?. **2005**, 20, 207-212		
476	Apport du dosage des chaînes légères libres d'immunoglobulines dans le diagnostic et le suivi des gammapathies monoclonales « chaînes légères. **2005**, 20, 385-393		
475	Bortezomib is effective in primary plasma cell leukemia. **2006**, 47, 1670-3		30
474	Proposed reference material for human free immunoglobulin light chain measurement. **2006**, 27, 129-37		4
473	Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. **2006**, 81, 1575-8		152
472	Systemic immunoglobulin light-chain amyloidosis. **2006**, 7, 182-5		17
471	Systemic amyloidosis. **2006**, 6, 214-20		73
470	Amyloidosis. **2006**, 57, 223-41		493
469	Dosage sérique des chaînes légères libres (CLL) d'immunoglobulines : de la biologie à la clinique. **2006**, 21, 270-278		
468	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. **2006**, 107, 3378-83		198
467	Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. **2006**, 107, 3854-8		209
466	Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. **2006**, 108, 2013-9		66
465	Amyloses. **2006**, 1, 1-8		
464	Protéinurie. **2006**, 1, 1-5		
463	Recurrent subconjunctival and periorbital haemorrhage as the first presentation of systemic AL amyloidosis secondary to myeloma. **2006**, 20, 512-5		8
462	The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. *Clinical Chemistry*, **2006**, 52, 1223-37	5.5	295
461	Amyloidosis. **2006**, 7, 225-36		31
460	Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. **2006** , 533, 319-26		50

459	Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. **2007**, 66, 23-7		105
458	Drug Insight: emerging therapies for amyloidosis. **2006**, 2, 263-70		26
457	The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains. **2006**, 47, 21-8		22
456	Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias. **2007**, 153, 44-65		16
455	Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis. **2007**, 153, 195-210		31
454	Primary (AL) amyloidosis in plasma cell disorders. **2006**, 11, 824-30		18
453	Localized oral amyloidosis of the palate. **2006**, 13, 42-6		20
452	Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis. **2006**, 13, 277-80		14
451	Immunochemical quantification of free immunoglobulin light chains from an analytical perspective. *Clinical Chemistry and Laboratory Medicine*, **2006**, 44, 522-32	5.9	23
450	Free light chain testing in follow-up of multiple myeloma. *Clinical Chemistry and Laboratory Medicine*, **2006**, 44, 1044-6	5.9	2
449	Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. *Clinical Chemistry*, **2006**, 52, 1743-8	5.5	87
448	Serum free light chain specificity and sensitivity: a reality check. *Clinical Chemistry*, **2006**, 52, 1638-9	5.5	11
447	Coelution of other proteins with albumin during size-exclusion HPLC: Implications for analysis of urinary albumin. *Clinical Chemistry*, **2006**, 52, 389-97	5.5	66
446	Chapter 21 Amyloidosis. **2007**, 7, 383-396		1
445	Free light chains. **2007**, 44, 503-5		11
444	Serum free light chains; the need to establish local reference intervals. **2007**, 44, 512-5		22
443	Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies?. **2007**, 44, 516-22		45
442	Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis. **2007**, 22, 1608-18		58

441	Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. **2008**, 23, 941-51		78
440	New screening diagnostic techniques in urinalysis. **2007**, 62, 155-61		27
439	Recommendations for use of Tumor Markers in Monoclonal Gammopathies. **2007**, 26, 165-172		
438	The Importance of Free Light Chains of Immunoglobulins Determination in Serum. **2007**, 26, 269-273		
437	Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results. **2007**, 127, 746-51		14
436	3-O-methyldopamine (3-O-methoxytyramine) interferes with the internal standard 3,4-dihydroxybenzylamine in a plasma catecholamine HPLC method. *Clinical Chemistry*, **2007**, 53, 1976-7	5.5	1
435	To the editor: in reply to Nakano et al. Clin Chem Lab Med 2006;44(5):522-532. *Clinical Chemistry and Laboratory Medicine*, **2007**, 45, 264-5; author reply 266-7	5.9	2
434	To the Editor: Author reply; Nakano et al. Clin Chem Lab Med 2006;44(5):522-532. *Clinical Chemistry and Laboratory Medicine*, **2007**, 45,	5.9	
433	Risk of antigen excess in serum free light chain measurements. *Clinical Chemistry*, **2007**, 53, 1985-6	5.5	38
432	Managing systemic light-chain amyloidosis. **2007**, 5, 179-87		37
431	Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. **2007**, 92, 143-4		71
430	[New insights into monoclonal gammopathy and multiple myeloma]. **2007**, 28, 667-9		1
429	[Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy]. **2007**, 28, 689-97		4
428	Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. **2007**, 18, 886-95		201
427	[Malignant transformation of monoclonal gammopathy of undetermined significance]. **2007**, 36, 1985-96		2
426	Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. **2007**, 149, 231-5		49
425	[Multiple myeloma]. **2007**, 129, 104-15		6
424	Biological and clinical significance of monoclonal gammopathy. 138-154		

423	Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. **2007**, 37, 456-63		22
422	Light-chain removal by plasmapheresis in myeloma-associated renal failure. **2007**, 47, 511-4		46
421	Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis - a pilot study. **2007**, 7, 185		7
420	Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy. **2007**, 40, 351-4		13
419	Immunonephelometric quantification of specific urinary proteins versus a simple electrophoretic method for characterizing proteinuria. **2008**, 41, 418-22		3
418	Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. **2008**, 87, 439-49		74
417	Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. **2008**, 255, 1508-14		96
416	Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. **2008**, 9, 11		121
415	Laboratory characterizations on 2007 cases of monoclonal gammopathies in East China. **2008**, 5, 293-8		10
414	Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. **2008**, 32, 910-7		56
413	The evolving use of serum free light chain assays in haematology. **2008**, 141, 413-22		77
412	Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. **2008**, 143, 349-54		19
411	Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report. **2008**, 2, 380		11
410	Apport de l'électrophorèse capillaire et du dosage des chaînes légères libres dans l'exploration des immunoglobulines : le point de vue de l'immunologiste. **2008**, 23, 231-239		1
409	Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases. **2008**, 29, 170-4		51
408	Apport diagnostique du dosage des chaînes légères libres sériques d'immunoglobulines pour l'exploration des gammapathies monoconales. **2008**, 2008, 37-50		
407	Severe intrahepatic cholestasis, erythrocytosis and hypoglycemia: unusual presenting features of systemic AL amyloidosis. **2008**, 43, 375-9		8
406	Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46, 335-41	5.9	15

405	Quantification of urinary light chains. *Clinical Chemistry*, **2008**, 54, 1744-6	5.5	6
404	Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. **2008**, 130, 702-11		25
403	Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. **2008**, 3, 1684-90		233
402	Screening algorithms for monoclonal gammopathies. *Clinical Chemistry*, **2008**, 54, 1753-5	5.5	10
401	Familial myeloma. **2008**, 359, 152-7		62
400	Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease?. **2008**, 12, 667-76		36
399	Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. **2008**, 93, 459-62		51
398	Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis. **2008**, 47, 1783-90		10
397	Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. **2008**, 111, 785-9		293
396	Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia. **2008**, 93, 793-4		33
395	[A case of multiple myeloma showing marked differences in serum IgG levels between protein electrophoresis and turbidimetry]. **2008**, 28, 282-5		
394	[Serum free light chains for diagnosis and follow-up of multiple myeloma]. **2008**, 28, 169-73		7
393	Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. *Clinical Chemistry*, **2009**, 55, 1510-6	5.5	30
392	Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. *Clinical Chemistry*, **2009**, 55, 1646-55	5.5	99
391	Heavy/Light-chain analysis of monoclonal gammopathies. *Clinical Chemistry*, **2009**, 55, 1606-8	5.5	14
390	Serum free light chain immunoassay as an adjunct to serum protein electrophoresis and immunofixation electrophoresis in the detection of multiple myeloma and other B-cell malignancies. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 302-4	5.9	16
389	Screening for M-proteinemia: serum protein electrophoresis and free light chains compared. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 1507-11	5.9	4
388	Serum-free light chain analysis: works in progress. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 1021-2	5.9	8

387	Quantitation of serum free light chains does not compensate for serum immunofixation only when screening for monoclonal gammopathies. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 1109-15	5.9	6
386	Serum free light chains: diagnostic and prognostic value in multiple myeloma. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 1101-7	5.9	10
385	Screening panels for detection of monoclonal gammopathies. *Clinical Chemistry*, **2009**, 55, 1517-22	5.5	213
384	Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy. **2009**, 46, 407-12		11
383	Utility of Serum Free Light Chain Analysis When Screening for Lymphoproliferative Disorders. **2009**, 40, 325-329		13
382	Phosphoester hydrolysis by cerium(IV)-thiacalix[4]arene complexes and its application to immunoassay. **2009**, 394, 1471-6		4
381	[Current diagnostic and therapy of light chain amyloidosis]. **2009**, 30, 205-11		2
380	Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. **2009**, 144, 217-22		40
379	Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. **2009**, 144, 705-15		28
378	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. **2009**, 23, 215-24		559
377	High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid. **2009**, 119, 39-44		32
376	Dosage sfique des chaï nes lgres libres (CLL) dmmunoglobulines dans la recherche dne immunoglobuline monoclonale. tude ˆ partir dn recrutement hospitalier de 135´patients. **2009**, 24, 149-154		
375	Free light chains in plasma cell disorders: measurement and therapeutic implications. **2009**, 30, 21-23		
374	Serum free light chain assessment in monoclonal gammopathy and kidney disease. **2009**, 5, 621-8		46
373	Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. **2009**, 4, 745-54		180
372	Gamma-globulin levels in patients with community-acquired septic shock. **2009**, 32, 379-85		61
371	Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. **2009**, 94, 1094-100		29
370	Primary cutaneous localized amyloid elastosis. **2010**, 32, 86-90		10

369	Clinical importance of serum free light chain analysis. **2010**, 7, 229-231		3
368	Kidney disease associated with plasma cell dyscrasias. **2010**, 116, 1397-404		40
367	Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. **2010**, 116, 5126-9		125
366	Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. **2010**, 89, 291-7		21
365	A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. **2010**, 89, 1019-27		14
364	Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. **2010**, 85, 236-42		28
363	Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. **2010**, 85, 431-4		31
362	Serum free light chain analysis. **2010**, 85, 787-90		32
361	Identification of Biomarkers for Diagnosis of Amyloid Diseases: Quantitative Free Light-Chain Assays. **2010**, 689-697		
360	Serum immunoglobulin free light chains in severe forms of atopic dermatitis. **2010**, 71, 312-6		14
359	Frequency of altered monoclonal protein production at relapse of multiple myeloma. **2010**, 148, 659-61		12
358	Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. **2010**, 24, 1498-505		30
357	The spot urine protein/creatinine ratio is a simple, rapid and inexpensive method for monitoring patients with light-chain multiple myeloma. **2010**, 3, 419-21		
356	Analytical performance of the serum free light chain assay. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 73-9	5.9	30
355	Commentary. *Clinical Chemistry*, **2010**, 56, 19-20	5.5	1
354	Sharply increased serum free light-chain concentrations after treatment for multiple myeloma. *Clinical Chemistry*, **2010**, 56, 16-8	5.5	27
353	Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. **2010**, 63, 884-7		27
352	Recommendations for Use of Free Light Chain Assay in Monoclonal Gammopathies. **2010**, 29, 1-8		7

351	Comparison of serum immunofixation electrophoresis and free light chain assays in the detection of monoclonal gammopathies. **2010**, 10, 278-80	9
350	Ten years of improvement in the management of multiple myeloma: 2000-2010. **2010**, 10, 424-42	22
349	[Value of serum free light chains assay in plasma cell disorders]. **2010**, 135, 368-74	1
348	Quantitative assessment of serum free light chains in renal transplantation. **2010**, 42, 2861-3	4
347	Vaccination against tick-borne encephalitis virus tests specific IgG production ability in patients under immunoglobulin substitution therapy. **2010**, 28, 6621-6	11
346	Efficacy and outcome of autologous transplantation in rare myelomas. **2010**, 95, 2126-33	36
345	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. **2010**, 375, 1721-8	249
344	Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. **2011**, 22, 1129-36	144
343	Novel M-component based biomarkers in Waldenström's macroglobulinemia. **2011**, 11, 164-7	20
342	Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial. **2011**, 52, 1271-80	15
341	Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. **2011**, 179, 1978-87	100
340	Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma. **2011**, 412, 562-8	8
339	Transplantation vs. conventional-dose therapy for amyloidosis. **2011**, 23, 214-20	29
338	The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. **2011**, 118, 6353-61	32
337	Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. **2011**, 118, 2821-6	43
336	Familial monoclonal gammopathy: hyper-responsive B cells in unaffected family members. **2011**, 86, 396-404	8
335	Normalization of serum-free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity. **2011**, 30, 685-9	23
334	Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. **2011**, 86, 251-5	74

333	Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. **2011**, 86, 998-1000		25
332	Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. **2011**, 63, 891-8		52
331	A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. **2011**, 1814, 409-19		34
330	N Latex FLC - new monoclonal high-performance assays for the determination of free light chain kappa and lambda. *Clinical Chemistry and Laboratory Medicine*, **2011**, 49, 1323-1332	5.9	76
329	Serum free light chains and the risk of ESRD and death in CKD. **2011**, 6, 2829-37		25
328	Higher serum levels of free κ plus λ immunoglobulin light chains ameliorate survival of hemodialysis patients. **2011**, 34, 344-9		5
327	Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. **2011**, 29, 1620-6		56
326	Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. *Clinical Chemistry*, **2011**, 57, 1387-9	5.5	50
325	The anion gap and routine serum protein measurements in monoclonal gammopathies. **2011**, 6, 2814-21		6
324	Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias. **2011**, 7, 65-73		5
323	Detection of free light chain monoclonal proteins co-migrating with intact monoclonal proteins in patients with monoclonal gammopathy. **2012**, 49, 603-5		1
322	Onco-nephrology: glomerular diseases with cancer. **2012**, 7, 1701-12		70
321	Association of plasma cell subsets in the bone marrow and free light chain concentrations in the serum of monoclonal gammopathy patients. **2012**, 65, 758-61		6
320	Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. *Clinical Chemistry and Laboratory Medicine*, **2011**, 50, 489-95	5.9	37
319	Immunobiology of antigen-specific immunoglobulin free light chains in chronic inflammatory diseases. **2012**, 18, 2278-89		10
318	Combined analysis using extended renal reference range of serum free light chain ratio and serum protein electrophoresis improves the diagnostic accuracy of multiple myeloma in renal insufficiency. **2012**, 45, 740-4		7
317	Using single protein biomarkers to predict health and disease in diverse patient populations: a new role for assessment of immunoglobulin free light chains. **2012**, 87, 505-7		10
316	Recognition of Monoclonal Proteins in Hospitalized Patients. **2012**, 1, e378-e385		

315	Serum immunoglobulin heavy/light chain (HLC) and free light chain (FLC) concentrations at diagnosis in multiple myeloma and IgM malignant lymphoma patients with survival exceeding 10 years. **2012**, 43, 201-209	1
314	Leki immunomodulujące oraz inhibitory proteasomów w leczeniu chorych na szpiczaka plazmocytowego z niewydolnością nerek. **2012**, 43, 173-186	1
313	Management of myeloma-associated renal dysfunction in the era of novel therapies. **2012**, 5, 51-66; quiz 67-8	25
312	The ability to interact with cell membranes suggests possible biological roles for free light chain. **2012**, 142, 75-7	21
311	Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy. **2012**, 12, 12	13
310	Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD. **2012**, 5, 28	11
309	Clinical and preclinical validation of the serum free light chain assay: identification of the critical difference for optimized clinical use. **2012**, 89, 458-68	11
308	Extended use of serum free light chain as a biomarker in lymphoproliferative disorders: a comprehensive review. **2012**, 137, 890-7	28
307	The challenge of systemic immunoglobulin light-chain amyloidosis (Al). **2012**, 65, 609-42	21
306	Comparison of immunoglobulin free light chain (FLC), heavy chain/light chain (HLC) assays and immunofixation (IFE) in assessment of remission in multiple myeloma. **2012**, 43, 122-131	4
305	Novel approaches for reducing free light chains in patients with myeloma kidney. **2012**, 8, 234-43	25
304	The role of immunological assessment in patients with acute kidney injury and possible myeloma. **2012**, 19, 287-90	
303	Primary hepatic amyloidosis: a mini literature review and five cases report. **2012**, 11, 721-727	9
302	Milder phenotype of congenital muscular dystrophy in a novel POMT1 mutation. **2012**, 45, 752-5	5
301	Expanding the spectrum of monoclonal light chain deposition disease in muscle. **2012**, 45, 755-61	13
300	Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents. **2012**, 30, 156-62	8
299	The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. **2011**, 8, 43-51	178
298	Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. **2012**, 30, 1087-94	22

297	Serum immunoglobulin free light chains in patients with monoclonal gammapathies. **2012**, 153, 249-54	6
296	Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder. **2012**, 12, 1268-74	21
295	"Idiopathic Bence-Jones proteinuria": a new characterization of an old entity. **2013**, 92, 1263-70	4
294	Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine. **2013**, 391, 1-13	37
293	Assessment of the diagnostic performances of IgA heavy and light chain pairs in patients with IgA monoclonal gammopathy. **2013**, 46, 79-84	7
292	Evaluaci□n de la inmunofijaci□n s□rica frente al cociente de cadenas ligeras libres Kappa/Lambda en la confirmaci□n de componentes monoclonales de baja concentraci□n. **2013**, 6, 32-36	
291	Issues with Immunology and Serology Testing. **2013**, 295-304	
290	Free light chain assay: doing a "good job" in Job's syndrome. **2013**, 54, 1131-2	
289	A window into immunoglobulin quantitation and plasma cell disease: antigen epitopes defined by the junction of immunoglobulin heavy and light chains. **2013**, 27, 1-2	8
288	Serum free light chain reference values: a critical approach. **2013**, 46, 691-3	12
287	Quantification of serum free light chain kappa and lambda by the SPAPLUS analyser. **2013**, 46, 622-6	6
286	Evaluaci□n de un nuevo reactivo monoclonal, N-L□ex Free Light Chains, para la cuantificaci□n nefelom□trica de las cadenas ligeras Kappa y Lambda libres en suero. **2013**, 6, 18-25	1
285	Determination of □LC and □ndex in cerebrospinal fluid: a valid alternative to assess intrathecal immunoglobulin synthesis. **2013**, 263, 116-20	51
284	Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphoma. **2013**, 160, 63-9	12
283	Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma. **2013**, 90, 134-41	28
282	History of Multiple Myeloma. **2013**, 521-533	
281	Immunoglobulins and Laboratory Recognition of Monoclonal Proteins. **2013**, 565-588	1
280	Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation. **2013**, 48, 419-24	31

279	Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains. **2013**, 54, 123-32	9
278	Prevalence and incidence of anemia in the German Heinz Nixdorf Recall Study. **2013**, 92, 731-7	32
277	Challenges with serum protein electrophoresis in assessing progression and clinical response in patients with Waldenström macroglobulinemia. **2013**, 13, 247-9	6
276	Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. **2013**, 31, 96-102	44
275	Incidence of skeletal morbidity rates over time in patients with multiple myeloma-related bone disease as reported in randomized trials employing bone-modifying agents. **2013**, 2, 69-76	1
274	Serum Immunoglobulin Free Light Chain Assessment in IgG4-Related Disease. **2013**, 2013, 426759	12
273	Modern approaches to the treatment of amyloidosis: the critical importance of early detection in surgical pathology. **2013**, 20, 424-39	32
272	Verification of serum reference intervals for free light chains in a local South African population. **2013**, 66, 992-5	
271	Kidney disease and multiple myeloma. **2013**, 8, 2007-17	93
270	Prognostic significance of serum free light chains in chronic lymphocytic leukemia. **2013**, 2013, 359071	5
269	Serum free light chains as predictors of lymphomagenesis in patients with autosomal dominant hyper-immunoglobulin E syndrome (Job's syndrome). **2013**, 54, 1316-7	3
268	Replacing urine protein electrophoresis with serum free light chain analysis as a first-line test for detecting plasma cell disorders offers increased diagnostic accuracy and potential health benefit to patients. **2013**, 140, 890-7	23
267	Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions. **2013**, 4, 37-41	26
266	Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. **2013**, 95, 519-26	15
265	CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma. **2013**, 48, 121-7	8
264	Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?. **2013**, 5, 4	41
263	Polyclonal free light chains: promising new biomarkers in inflammatory disease. **2014**, 139	5
262	Serum levels of immunoglobulin free light chains in patients with chronic hepatitis C presenting cryoglobulinemia. **2014**, 18, 638-42	8

261	Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma. **2014**, 89, 1116-20		14
260	Utility of nine-color, 11-parameter flow cytometry for detection of plasma cell neoplasms: a comparison with bone marrow morphologic findings and concurrent M-protein studies in serum and urine. **2014**, 142, 398-410		5
259	Plasma cell neoplasms, their precursor States, and their prediction of organ damage. **2014**, 32, 2679-82		8
258	Value of antibodies to free light chains in immunoperoxidase studies of renal biopsies. **2014**, 67, 661-6		9
257	Serum Free Light Chain Only Myeloma with Cytoplasmic IgM. **2014**, 2014, 676913		2
256	Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. **2014**, 9, e88680		54
255	Association between the delta estimated glomerular filtration rate and the prevalence of monoclonal gammopathy of undetermined significance in Korean males. *BioMed Research International*, **2014**, 2014, 356080	3	1
254	An evaluation of current treatment options for immunoglobulin light-chain amyloidosis. **2014**, 2, 229-244		
253	Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. **2014**, 89, 417-22		16
252	The relationship between high-sensitivity CRP and polyclonal free light chains as markers of inflammation in chronic disease. **2014**, 36, 415-24		23
251	Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions. **2014**, 14, 55-66		26
250	Quantification of polyclonal free light chains in clinical samples using a single turbidimetric immunoassay. *Clinical Chemistry and Laboratory Medicine*, **2014**, 52, 1605-13	5.9	5
249	N Latex FLC serum free light-chain assays in patients with renal impairment. *Clinical Chemistry and Laboratory Medicine*, **2014**, 52, 853-9	5.9	23
248	Biochemical markers in early diagnosis and management of systemic amyloidoses. *Clinical Chemistry and Laboratory Medicine*, **2014**, 52, 1517-31	5.9	18
247	46th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC Laboratory Medicine). *Clinical Chemistry and Laboratory Medicine*, **2014**, 52,	5.9	
246	Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma. **2014**, 110, 2277-82		8
245	Serum immunoglobulin free light chain and heavy/light chain measurements in POEMS syndrome. **2014**, 93, 1201-6		14
244	Serum-free light-chain assay: clinical utility and limitations. **2014**, 51, 528-42		36

243	Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. **2014**, 25, 2124-2133		110
242	High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis. **2014**, 276, 175-9		45
241	The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma. **2014**, 38, 1291-8		5
240	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. **2014**, 15, e538-48		2253
239	The analytical performance evaluation of Freelite Human Kappa Free and Human Lambda Free on the SPAPLUS immunoturbidimetric analyzer. **2014**, 28, 229-36		2
238	Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification. **2014**, 93, 1867-77		11
237	The peptidic middle molecules: is molecular weight doing the trick?. **2014**, 34, 118-34		23
236	Comments on CSF FLC assay evaluation in assessing intrathecal synthesis. **2014**, 266, 89		1
235	Serum free light chains in clinical laboratory diagnostics. **2014**, 427, 15-20		50
234	Multiple Myeloma and Evolution of Novel Biomarkers and Therapies. **2014**, 871-908		
233	The expression and significance of immunoglobulin free light chain in the patients with allergic rhinitis and nonallergic rhinitis. **2014**, 28, 302-7		4
232	Light Chain Escape Multiple Myeloma Complicated with Catastrophic Extramedullary Plasmacytoma Following Novel Agent Treatment. **2014**, 1, 39-45		
231	Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival. **2014**, 32, 205-11		2
230	Comparison of the Freelite serum free light chain (SFLC) assay with serum and urine electrophoresis/immunofixation and the N Latex FLC assay. **2015**, 47, 564-9		7
229	Effect of specimen type on free immunoglobulin light chains analysis on the Roche Diagnostics cobas 8000 analyzer. **2015**, 4, 760		8
228	Immunoparesis in MGUS - Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories. **2015**, 62, 827-32		6
227	Effectiveness of Haemodiafiltration with Heat Sterilized High-Flux Polyphenylene HF Dialyzer in Reducing Free Light Chains in Patients with Myeloma Cast Nephropathy. **2015**, 10, e0140463		14
226	Comment on "Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy". *BioMed Research International*, **2015**, 2015, 742762	3	1

225	Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. **2015**, 17, 92	45
224	Serum free light chains in patients with HIV infection: their association with markers of disease severity and antiretroviral use. **2015**, 68, 148-53	8
223	The association of serum-free light-chain levels with markers of renal function. **2015**, 37, 1057-60	5
222	Diagnosis of monoclonal gammopathy of renal significance. **2015**, 87, 698-711	261
221	Clinical Course and Prognosis of Non-Secretory Multiple Myeloma. **2015**,	4
220	Clinical course and prognosis of non-secretory multiple myeloma. **2015**, 95, 57-64	33
219	Quantitative measurement of immunoglobulins and free light chains using mass spectrometry. **2015**, 87, 8268-74	19
218	Calorimetric features of IgM gammopathies. Implication for patient diagnosis and monitoring. **2015**, 615, 23-29	13
217	Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure. **2015**, 3, 618-25	14
216	Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma. **2015**, 15, 541-5	5
215	Circulating monoclonal light chains and acute kidney injury: the role of the renal biopsy with emphasis on ultrastructural evaluation in assessing and understanding renal injury. **2015**, 39, 159-68	1
214	The serological diagnostic challenges of multiple myeloma. **2015**, 76, 84-8	1
213	Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. **2015**, 15, 650-8	55
212	Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis. **2015**, 8, 264-8	11
211	LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens. **2015**, 94, 330-5	16
210	Smoldering multiple myeloma. **2015**, 125, 3069-75	159
209	Polyclonal versus monoclonal immunoglobulin-free light chains quantification. **2015**, 52, 327-36	17
208	A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred. **2015**, 22, 26-30	2

207	Guidelines on the diagnosis and investigation of AL amyloidosis. **2015**, 168, 207-18		88
206	High incidence of intact or fragmented immunoglobulin in urine of patients with multiple myeloma. **2015**, 56, 3348-56		2
205	IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay. **2015**, 63, 210-4		7
204	Amyloid and Related Disorders. **2015**,		6
203	Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD). **2015**, 63, 17-20		5
202	Cancer and Chronic Kidney Disease. **2015**, 571-584		1
201	Light chain multiple myeloma: when the response will it be evaluated by serum free light chains?. **2016**, 22, 393-394		
200	Benefits of new immunoglobulin-derived biomarkers for the diagnosis and follow-up of patients with dysglobulinemia. **2016**, 74, 597-605		1
199	Antiallergic effects of anti-interleukin-33 are associated with suppression of immunoglobulin light chain and inducible nitric oxide synthase. **2016**, 30, 17-22		2
198	Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma. **2016**, 174, 536-40		3
197	Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 907-19	5.9	40
196	Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. **2016**, 128, 2941-2948		39
195	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. **2016**, 133, 2404-12		792
194	Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. **2016**, 101, 356-62		16
193	Strengths and weaknesses of methods for identifying monoclonal free light chains of Ig: examples from two cases with renal disease. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 1039-43	5.9	2
192	Free light chains and heavy/light chains in monitoring POEMS patients. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 1065-71	5.9	2
191	Laboratory testing in monoclonal gammopathy of renal significance (MGRS). *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 929-37	5.9	27
190	Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 997-1003	5.9	18

189	Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. **2016**, 23, 214-220		5
188	Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports. **2016**, 12, 2363-2370		2
187	Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions. **2016**, 245, S113-8		5
186	Systemic amyloidosis: novel therapies and role of biomarkers. **2017**, 32, 770-780		33
185	Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance. **2016**, 11, 2280-2287		29
184	Evaluation of the Impact of Renal Failure on Correlation and Concordance Between 2 Free Light Chain Assays. **2016**, 16, 693-704		6
183	Multiple myeloma: disease response assessment. **2016**, 9, 831-7		7
182	Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology. **2016**, 29, 735-746		14
181	Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. **2016**, 96, 119-27		7
180	Occurrence of Double Monoclonal Bands on Protein Electrophoresis: An Unusual Finding. **2016**, 32, 184-8		6
179	Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency and usual COPD. **2016**, 17, 34		9
178	Is accuracy of serum free light chain measurement achievable?. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 1021-30	5.9	26
177	Measurement of free light chains - pros and cons of current methods. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 1015-20	5.9	14
176	Systemic amyloidoses and proteomics: The state of the art. **2016**, 11, 4-10		11
175	Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. **2016**, 57, 2058-64		9
174	Monitoring free light chains in serum using mass spectrometry. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 1073-83	5.9	24
173	Old but Still Relevant: High Resolution Electrophoresis and Immunofixation in Multiple Myeloma. **2016**, 32, 10-7		5
172	Challenges of measuring monoclonal proteins in serum. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 947-61	5.9	35

171	Hemodiafiltration improves free light chain removal and normalizes κ/λ ratio in hemodialysis patients. **2016**, 29, 251-257		14
170	Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study. **2016**, 22, 502-10		61
169	Minimal residual disease testing after stem cell transplantation for multiple myeloma. **2016**, 51, 2-12		15
168	Multiple sclerosis: assay of free immunoglobulin light chains. **2017**, 54, 5-13		16
167	Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. **2017**, 35, 195-201		9
166	Determination of proteins in blood. Part 2: Determination of globulins. **2017**, 7, 147-221		
165	The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases. **2017**, 91, 632-644		11
164	Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion. **2017**, 190, 133-142		6
163	Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. **2017**, 178, 220-230		20
162	AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. **2017**, 130, 632-642		74
161	Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. **2017**, 130, 625-631		86
160	Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 1734-1743	5.9	24
159	Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents. **2017**, 102, e104-e107		10
158	Stone former urine proteome demonstrates a cationic shift in protein distribution compared to normal. **2017**, 45, 337-346		9
157	Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 424-434	5.9	18
156	Free light chains: Eclectic multipurpose biomarker. **2017**, 451, 11-19		24
155	Effect of autologous stem-cells transplantation of patients with multiple myeloma on the calorimetric markers of the serum proteome. Correlation with the immunological markers. **2017**, 655, 351-357		4
154	Characteristics of Vitamin B12 Deficiency in Patients With Plasma Cell Disorders. **2017**, 17, e65-e69		3

153	Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry. **2017**, 37, 821-853		15
152	Determination of proteins in blood. Part 3: Systematization of methods for the determination of protein compounds in blood. **2017**, 7, 261-333		
151	Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. **2017**,		1
150	Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance. **2017**, 30, 457-463		21
149	A novel approach for the chromatographic purification and peptide mass fingerprinting of urinary free light chains. **2017**, 95, 331-339		3
148	A Study on Free Light Chain Assay and Serum Immunofixation Electrophoresis for the Diagnosis of Monoclonal Gammopathies. **2019**, 34, 76-81		
147	The Diagnostic Path of Amyloidosis. When to Think of it and how to Find it. **2017**, 29, 157-162		2
146	Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases. **2017**, 18,		4
145	Persistent Back Pain and Normal Serum Immunofixation in an Older Gentleman. **2017**, 2, 269-272		
144	AL amyloidosis: from molecular mechanisms to targeted therapies. **2017**, 2017, 1-12		77
143	CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 1071-1080	5.9	28
142	Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. **2018**, 32, 1815-1818		12
141	Antigen excess detection by automated assays for free light chains. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, e235-e238	5.9	3
140	History of Multiple Myeloma. **2018**, 511-524		
139	Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. **2018**, 51, 38-47		25
138	Evaluation of the N-latex serum free light chain assay on the Siemens BNII analyzer and agreement with The Binding Site FreeLite assay on the SPA. **2018**, 51, 90-96		11
137	Synoptic reporting for protein electrophoresis and immunofixation. **2018**, 51, 21-28		7
136	Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. **2018**, 32, 729-735		36

135	Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 312-322	5.9	15
134	Étude du comportement du rapport kappa/lambda des chaînes légères libres sériques (test Freelite) et du rapport Ig kappa/Ig lambda (test Hevylite) chez 32 patients adultes atteints de PTI (purpura thrombopénique immunologique). **2018**, 39, A152-A153		
133	Evaluation of the new Sebia free light chain assay using the AP22 ELITE instrument. **2018**, 487, 161-167		6
132	Recent advances in understanding and treating immunoglobulin light chain amyloidosis. **2018**, 7,		9
131	Humoral immunity in late-onset Pre-eclampsia and linkage with angiogenic and inflammatory markers. **2018**, 80, e13041		11
130	Immunochemical Diagnosis of Multiple Myeloma. **2018**, 165, 84-87		2
129	Reference ranges of the Sebia free light chain ratio in patients with chronic kidney disease. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, e232-e234	5.9	8
128	[Diagnostic accuracy of serum protein electrophoresis and free light chain measurements for monoclonal gammopathies]. **2018**, 146, 64-67		2
127	Cerebrospinal fluid free kappa light chains and kappa index perform equal to oligoclonal bands in the diagnosis of multiple sclerosis. *Clinical Chemistry and Laboratory Medicine*, **2018**, 57, 210-220	5.9	17
126	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. **2018**, 93, 1207-1210		1
125	Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis. **2018**, 89, 1044-1049		18
124	Reference intervals and diagnostic ranges for serum free κ and free λ immunoglobulin light chains vary by instrument platform: Implications for classification of patient results in a multi-center study. **2018**, 58, 100-107		11
123	Sources of errors in immunology and serology testing. **2019**, 329-333		
122	Heavy/light chain assay in the monitoring of multiple myeloma. **2019**, 51, 507-511		3
121	Is urine immunofixation electrophoresis necessary for monitoring myeloma patients who have undergone hematopoietic stem cell transplantation?. **2019**, 58, 102660		0
120	Serum-free light chains adjusted for renal function are a potential biomarker for post-transplant lymphoproliferative disorders. **2019**, 98, 625-632		3
119	Smoldering Multiple Myeloma: To Treat or Not to Treat. **2019**, 25, 65-71		12
118	Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry. *Clinical Chemistry*, **2019**, 65, 1015-1022	5.5	18

117	Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, 1397-1405	5.9	3
116	Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease. **2019**, 2, e113		6
115	CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort. **2019**, 10, 641		23
114	[Free light chains assay: Indications and methods]. **2019**, 40, 297-305		3
113	Nanoporous silica coupled MALDI-TOF MS detection of Bence-Jones proteins in human urine for diagnosis of multiple myeloma. **2019**, 200, 288-292		15
112	Utility of the Serum Free Light Chain Assay in the Diagnosis of Light Chain Amyloidosis in Patients With Heart Failure. **2019**, 94, 447-454		2
111	Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma. **2019**, 19, e228-e237		4
110	Immunoglobulin free light chains and interleukin-6 levels in prediction of kidney injury in patients with multiple myeloma. **2019**, 10, 1-7		
109	Laboratory testing in the evaluation of a monoclonal protein: A practical framework for interpretation. **2019**, 109, 719		
108	Method comparison of four clinically available assays for serum free light chain analysis. *Clinical Chemistry and Laboratory Medicine*, **2019**, 58, 85-94	5.9	10
107	[Monoclonal gammopathy of undetermined significance (MGUS): interpretative shades of analysis and sometimes serious clinical consequences]. **2019**, 77, 245-254		
106	AL amyloidosis: advances in diagnostics and treatment. **2019**, 34, 1460-1466		31
105	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. **2020**, 26, 912-923		26
104	Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory. **2020**, 57, 73-85		7
103	Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases. **2020**, 199, 163-171		11
102	Cancer and Chronic Kidney Disease. **2020**, 899-917		1
101	Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma. **2020**, 10, 2		10
100	The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL). **2020**, 61, 1133-1139		2

99	In-house age-specific reference ranges for free light chains measured on the SPAPlus analyser. **2020**, 57, 138-143	1
98	Cast nephropathy. **2020**, 59-66.e3	
97	Analytical validation of new ELISAs for the quantitation of polyclonal free light chains and comparison to existing assays for healthy and patient samples. **2020**, 478, 112713	1
96	How to quantify monoclonal free light chains in plasma cell disorders: which mass spectrometry technology?. **2020**, 8, 973	1
95	Free light chain UV quantification compared with immunochemical measurement: How dimers and monomers may influence the results. **2020**, 510, 278-284	1
94	Clinically-suspected cast nephropathy: A retrospective, national, real-world study. **2020**, 95, 1352-1360	6
93	Detection of monoclonal free light chains by immunofixation electrophoresis and isoelectric focusing - comparison with the quantitative method of determination. **2020**, 80, 556-561	0
92	Limitations of Free Light Chain Assays caused by the Matrix Effect. **2020**, 5, 311-319	1
91	Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study. **2020**, 10, 28	12
90	and urine free light chains: a new method for quantification. **2020**, 106, 457-463	
89	Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. **2020**, 5, 627-631	7
88	Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype. **2020**, 11, 319	2
87	The renal range of the sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease. **2020**, 21, 111	4
86	High-Throughput Therapeutic Antibody Interference-Free High-Resolution Mass Spectrometry Assay for Monitoring M-Proteins in Multiple Myeloma. **2021**, 93, 834-842	5
85	Protein Electrophoresis, Serum Free Light Chain Assay and Other Biomarkers in Diagnosis and Monitoring of Monoclonal Protein Associated Disease. **2021**,	
84	Oligoclonal Bands: Isoelectric Focusing and Immunoblotting, and Determination of Free Light Chains in the Cerebrospinal Fluid. **2021**, 29-54	
83	Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. **2021**, 11, 24	24
82	Immunoglobulin light chain amyloidosis. **2021**, 14, 103-110	0

81	Serum free light chains in solid organ transplant recipients. **2021**, 35, e14286		1
80	Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. **2021**, 11, 94		11
79	Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management. **2021**, 16, 357-366		1
78	Clinical Mass Spectrometry Approaches to Myeloma and Amyloidosis. **2021**, 41, 203-219		3
77	Multiple Myeloma, Hyperviscosity, Hemodialysis Filter Clogging, and Antigen Excess Artifact: A Case Report. **2021**, 3, 649-652		
76	Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications. **2021**, 43 Suppl 1, 43-53		3
75	Acute Kidney Injury in Monoclonal Gammopathies. *Journal of Clinical Medicine*, **2021**, 10,	5.1	1
74	Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. **2021**, 149, 1980-1996		5
73	Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology. **2021**,		1
72	Comparison of Freelite and N-Latex serum free light chain assays: a critical review. **2021**, 31, 030701		2
71	Using quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify low level monoclonal proteins. **2021**, 95, 81-83		0
70	Kappa/Lambda Ratio for Early Detection of Multiple Myeloma Relapse Using the Reference Change Value from Biological Variation Studies. **2021**, 6, 1683-1687		
69	Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. **2021**, 13,		0
68	Laboratory Support for Diagnosis of Amyloidosis. **2012**, 275-282		1
67	Myeloma and Secondary Involvement of the Kidney in Dysproteinemias. **2008**, 461-468		1
66	Proteins identified by serum protein electrophoresis. **2003**, 63-108		3
65	A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli. **2013**, 8, e76022		17
64	The Association between Polyclonal Combined Serum Free Light Chain Concentration and Mortality in Individuals with Early Chronic Kidney Disease. **2015**, 10, e0129980		9

63	Assessment of Intrathecal Free Light Chain Synthesis: Comparison of Different Quantitative Methods with the Detection of Oligoclonal Free Light Chains by Isoelectric Focusing and Affinity-Mediated Immunoblotting. **2016**, 11, e0166556	13
62	Evaluation of the Screening Tests for the Diagnosis of Plasma Cell Neoplasm. **2012**, 2, 80	2
61	Production and Purification of Polyclonal Antibody Against Human Kappa Light Chain. **2008**, 8, 683-686	3
60	Significance of Proliferation Markers and Prognostic Factors in Egyptian Patients with Multiple Myeloma. **2016**, 17, 1351-5	3
59	Conditions associated with monoclonal gammopathies. **2003**, 145-216	
58	Examination of urine for proteinuria. **2003**, 217-258	
57	Renal Diseases Associated With Multiple Myeloma and Related Plasma Cell Dyscrasias. **2004**, 281-302	
56	AL amyloidosis. **2004**, 400-419	
55	Diagnostic Value of Free Kappa and Lambda Light Chains in Fat Tissue of Patients with Systemic Al Amyloidosis. **2004**, 107-108	
54	Serum Levels of Free Kappa and Lambda Light Chains in Patients with Systemic Al, Aa, and Attr Amyloidosis. **2004**, 105-106	
53	Quantitative Serum Free Light-Chain Assay in the Diagnostic Evaluation of Al Amyloidosis. **2004**, 90-92	
52	Serum Levels of Free Kappa and Lambda Light Chains in Patients with Systemic AL, AA, and ATTR Amyloidosis. **2004**, 105-106	
51	Diagnostic Value of Free Kappa and Lambda Light Chains in Fat Tissue of Patients with Systemic AL Amyloidosis. **2004**, 107-108	
50	Immunoglobulin Patterns in Health and Disease. **2005**, 235-267	
49	Immunoglobulin Quantification and Viscosity Measurement. **2006**, 69-74	1
48	L. **2007**, 747-868	
47	A Supervised Analysis of Gene-Expression Profiles of Purified Clonal Plasma Cells from Patients with Systemic Light-Chain Amyloidosis (Al) who have High or Low Levels of Serum Free Lambda Light Chains. **2007**, 237-239	
46	Nosologie et prise en charge des gammapathies monoclonales. **2009**, 193, 1069-1087	

45 Laboratory test for amyloidosis. **2010**, 54, 27-29

44 AL amyloidosis and abnormalities of fibrinolysis. **2010**, 21, 9-15

43 Kapitel E1 Literaturverzeichnis zu Peter, Pichler, M□ller-Ladner (Hrsg.): Klinische Immunologie. **2012**, e1-e80

42 Free Immunoglobulin Light Chains. 279-291

41 L. **2013**, 825-902

40 Detection of M Proteins. **2014**, 17-25

39 Evaluation of the Effectiveness of the Heavy-Light Chain Quantitative Test. **2015**, 5, 127

38 Laboratory Support for Diagnosis of Amyloidosis. **2015**, 333-341

37 Serum Free Light Chain Analysis. **2016**, 25-42 2

36 Serum monoclonal and polyclonal free light chains in newly diagnosed Egyptian patients with diffuse large B-cell lymphoma: their impact on event-free and overall survival. **2016**, 41, 56

35 Immunoglobulin Quantification and Viscosity Measurement. 65-73

34 Leichtketten, Serum und Urin. **2017**, 1-2

33 Cardiac AL Amyloidosis □the role of serum Immunoglobulin Free Llight Chain assay (sFLC) in diagnosis and prognostic classification. **2017**, 53, 175-184

32 Leichtketten, Serum und Urin. **2019**, 1446-1447

31 Plasma Cell Neoplasms (Including Plasma Cell Myeloma). **2020**, 595-614

30 Multiples Myelom. 421-455

29 Immunoglobulin free light chains in developing and progression of kidney diseases. *Nephrology (Saint-Petersburg)*, **2021**, 25, 27-38 0.4

28 What Do The Elevated Protein Levels Mean In My Patients With Myeloma, Amyloidosis, and Related Disorders?. *American Journal of Medicine*, **2022**, 2.4

27	Physiology, Diagnosis and Treatment of Cardiac Light Chain Amyloidosis.. *Journal of Clinical Medicine*, **2022**, 11,	5.1	2
26	Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis-from diagnosis to prediction of disease activity.. *Wiener Medizinische Wochenschrift*, **2022**, 1	2.9	0
25	Detection of paraprotein in plasma cell tumors. *Terapevticheskii Arkhiv*, **2022**, 94, 135-144	0.9	1
24	Combined Immunoglobulin Free Light Chains Are Novel Predictors of Cardiovascular Events in Patients With Abdominal Aortic Aneurysm.. *European Journal of Vascular and Endovascular Surgery*, **2022**,	2.3	0
23	Using Two Detection Methods to Observe the Changes and Significance of Free Light Chain in Serum and Urine in Patients with Renal Insufficiency.. *BioMed Research International*, **2022**, 2022, 5536199	3	0
22	Method comparison of three serum free light chain assays on the Roche Cobas 6000 c501 chemistry analyzer.. *Clinical Chemistry and Laboratory Medicine*, **2021**,	5.9	
21	Image_1.jpg. **2020**,		
20	Image_2.jpg. **2020**,		
19	Table_1.docx. **2020**,		
18	Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges.. *International Journal of Nephrology and Renovascular Disease*, **2022**, 15, 173-183	2.5	0
17	Mono/polyclonal free light chains as challenging biomarkers for immunological abnormalities. *Advances in Clinical Chemistry*, **2022**, 155-209	5.8	0
16	The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria. *Brain*,	11.2	0
15	A simple scheme for large scale purification of urine Derived Bence Jones Kappa protein. **2022**, 1210, 123452		0
14	Role of serum free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.		0
13	Accuracy of determination of free light chains (Kappa and Lambda) in plasma and serum by Swedish laboratories as monitored by external quality assessment. **2022**,		0
12	Biochemical profile of Bence-Jones type multiple myeloma. **2022**, 67, 570-574		0
11	Chicken antibodies are highly suitable for particle enhanced turbidimetric assays. 13,		0
10	Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement. 135245852211342		0

9	Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis. 135245852211342	0
8	Use of Clinical Decision Support to Improve the Laboratory Evaluation of Monoclonal Gammopathies.	0
7	Bad players in AL amyloidosis in the current era of treatment. 1-17	0
6	Serum free light chains benefit diagnosis of multiple myeloma in orthopaedic patients with normal serum total proteins, creatinine, calcium and hemoglobin.	0
5	Rapid detection of serum free light chains by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. **2023**, 29, 132-140	0
4	First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium. **2023**, 23, 340-354	0
3	Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis.	0
2	Non-invasive monitoring associated with B lymphoma cells in post-transplant lymphoproliferative disorder (PTLD) patients: Systematic review. **2023**, 1-12	0
1	A Single Reference Interval for Interpreting Serum Free Light Chains across Patients with Varying Renal Function.	0